Table 1.
Demographic and clinical characteristics of the study population at person level and joint level.
| Study participants included, N=285 | |
|---|---|
| Age, median (IQR) years | 61 (57, 66) |
| Sex, n (%) women | 251 (88) |
| Fulfilment of ACR hand OA criteria, n (%) | 268 (94) |
| Body mass index, mean (SD) | 26 (5) |
| Symptom duration, median (IQR) years | 6 (3, 13) |
| Numeric Rating Scale of hand pain last 24 hours, mean (SD) [0–10] | 3.8 (2.3) |
| Regular use of analgesics, n (%) | |
| Acetaminophen | 11 (4) |
| Oral or topical nonsteroidal anti-inflammatory drugs | 35 (12) |
| Opioids or opioid-like drugs | 5 (2) |
| Antiepileptics, TCA and/or SNRI | 15 (5) |
| KL sum score, median (IQR) [0–128] 1 | 28 (16, 43) |
| Erosive OA, n (%)2 | 101 (35) |
| Grey Scale synovitis sum score, median (IQR) [0–90] 1 | 3 (1, 7) |
| Number of joints with Power Doppler activity grade 1–3, median (IQR) [0–30]1 | 1 (0, 3) |
| Finger joints included3, N=570 | |
| Joints with Kellgren-Lawrence grade n (%) | 290 (51) |
| Erosive joint disease, n (%) | 63 (11) |
| Grey Scale synovitis grade 1–3, n (%) | 147 (26) |
| Power Doppler activity grade 1–3, n (%) | 98 (17) |
IQR; interquartile range, ACR; American College of Rheumatology, OA; osteoarthritis, SD; standard deviation, TCA; tricyclic antidepressants, SNRI; serotonin-norepinephrine reuptake inhibitor.
1
Including the bilateral distal and proximal interphalangeal, metacarpophalangeal, first carpometacarpal and scaphotrapeziotrapezoidal joints.
2
Erosive hand OA = at least one interphalangeal joint in the Verbuggen-Veys erosive or remodelling phases.
3
Two joints per participant; The most painful joint and a random non-painful joint among the 2nd-5th distal and 1st-5th proximal interphalangeal joints.